• For H1-2016, Bionaturis Group Reports Revenue of €2.25 Million, Growing €1.36 Million, and EBITDA of €645 Thousand, Growing €1.01 Million
  • The biotech group also reports the full acquisition of ZIP Solutions as one of the relevant accomplished milestones for the period
  • The ZIP Solution acquisition transaction was triggered after the signing of a worldwide exclusive license agreement of Splittera to a leading multinational company

JEREZ DE LA FRONTERA (CADIZ). SPAIN.—BIONATURIS GROUP (trading symbol BNT) today reported its financial audited consolidated results for the first half of 2016.

The biotech group reported revenue of €2.25 Million for the first half of 2016, an increase of €1.36 Million (or 155%) compared with same period of 2015. EBITDA for the first half of 2016 was €0.65 Million, compared with €-0.37 Million for the first half of 2015, on a reported basis.

According to the report, Bionaturis Group keeps the pace of continuous growth in many of its main performance indicators at organic level. Thus, the recurring business follows the growing trend registered in recent years showing a 12% increase on net sales.  The organic growth has been accompanied by the strategic inorganic one througout M&A transactions. As such, within H1-2016 Bionaturis Group closed the 100% acquisition of the biotech company Zera Inteins Solutions (“ZIP“), triggered after the signing of a worldwide exclusive license of the Splittera system by ZIP to a top multinational company. As a result of the transaction, the biotech investment fund -Inveredy Innvierte Biotech II- got a 8.98% stake of Bionaturis.

Within the international expansion strategy, the biotech group reported the establishment of the Chinese subsidiary BNT China Biosciences, created to levearage the promotion of the premium offer of the group to the Asian-Pacific market from the field. Another reported relevant milestone achieved during H1-2016 has been the signing of a contract between Biobide (Bionaturis Group) and the National Institute of Environmental Health Sciences in United States, part of the prestigious National Institute of Health.

For the official disclosing, please, click here (Only in Spanish)

DISCLOSURE NOTICES

Forward-Looking Statements : This release contains forward-looking statements, which reflect the current views of Bionaturis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Bionaturis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. 

Internet Posting of Information : We routinely post information that may be important to investors in the ‘Investors’ section of our website at www.bionaturisgroup.com  and on our social media zone. We encourage investors and potential investors to consult our website regularly and to follow us on LinkedIn, Youtube channel and Twitter for information about us.